India is facing a significant healthcare burden due to the prevalence of diabetes, which has reached epidemic proportions. The International Diabetes Federation (IDF) reports that over 65 million people in India have diabetes, up from 50.8 million in 2011, and this number is expected to increase to 109 million by 2035. Unfortunately, many people with diabetes are unaware of their condition, which can lead to serious health problems such as heart attack, stroke, amputations, nerve damage, blindness, and kidney disease.
Micro Labs, one of the major players in the Indian pharmaceutical market in diabetes care, recognized the need to address this issue and established the Diabetes Taskforce (DTF) in 2005. The DTF's goal was to provide comprehensive diabetes care—ranging from the management of Hyperglycemia to Hypoglycemia and related complications—at affordable prices to Indian patients. In just ten years, Micro Labs had become the seventh-ranked company in the AWACS sales audit, with several of its diabetic brands, including Diapride, Tripride, Vildapride, Tenepride, Zucapride, Sitapride, Linapride, Dianorm, Voglinorm, Sitanorm, Vilpower proving to be highly effective in the treatment of diabetes and therefore performing well in their respective markets.
Micro Labs exhibits a full-fledged approach in the treatment of diabetes offering a range of services to patients and healthcare providers, including diabetes education. In a country where there is a shortage of diabetes care professionals, education plays a crucial role in managing this fast-growing epidemic. Over the years, Micro Labs is known for publishing scientific book on diabetes every year since 20+ years that are highly regarded by Indian clinicians. These one-of-its-kind initiative offer an Indian perspective on treating diabetes.
We conduct diabetes screening & awareness campaigns across the country in partnership with media and diabetes care providers and screen about 200,000 individuals every year. This initiative helps patients to avoid future complications that could arise due to unchecked blood sugar levels. We also have a strong sense of social responsibility, which is built into our corporate mission.
We primarily cater to the following disease areas under this therapy:
Group of drugs that lower blood sugar levels in patients suffering from diabetes mellitus.
These group of drugs are hormone mimickers which regulates hormones imbalances in the human body and promotes healing.